BioSig (BSGM) 10-K 27 Feb 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 27, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		29,998,466
Entity Public Float			$ 24,577,543
Amendment Flag	false
Entity Central Index Key	1,530,766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 1,547,579	$ 1,055,895
Prepaid expenses	116,938	134,263
Total current assets	1,664,517	1,190,158
Property and equipment, net	18,716	24,188
Other assets:
Deposits	17,084	27,612
Total assets	1,700,317	1,241,958
Current liabilities:
Accounts payable and accrued expenses, including $27,375 and $15,755 to related parties as of December 31, 2017 and 2016, respectively	473,098	373,103
Dividends payable	447,901	359,891
Warrant liability	2,358,240	1,937,234
Derivative liability	685,922	288,934
Total current liabilities	3,965,161	2,959,162
Convertible Preferred Stock	985,000	1,070,000
Stockholders’ deficit
Preferred stock
Common stock, $0.001 par value, authorized 200,000,000 shares, 29,321,204 and 22,588,184 issued and outstanding as of December 31, 2017 and 2016, respectively	29,321	22,588
Additional paid in capital	53,215,635	41,019,251
Commitments and contingencies	29,985
Accumulated deficit	(56,524,786)	(43,829,043)
Total stockholders’ deficit	(3,249,844)	(2,787,204)
Total liabilities and stockholders’ deficit	1,700,317	1,241,958
Series C Preferred Stock [Member]
Current liabilities:
Dividends payable	419,283	359,891
Series D Preferred Stock [Member]
Stockholders’ deficit
Preferred stock	$ 1	$ 0

BALANCE SHEETS (Parentheticals)

BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accounts payable and accrued expenses, related parties (in Dollars)	$ 27,375	$ 15,755
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred Stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	29,321,204	22,588,184
Common stock, shares outstanding	29,321,204	22,588,184
Series C Preferred Stock [Member]
Preferred stock, shares issued	985	1,070
Preferred stock, shares outstanding	985	1,070
Preferred stock, liquidation preference (in Dollars)	$ 985,000	$ 1,070,000
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600
Series D Preferred Stock [Member]
Preferred stock, liquidation preference (in Dollars)	$ 2,001,000	$ 0
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,400
Preferred Stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred Stock, shares issued	1,334,000,000	0
Preferred Stock, shares outstanding	1,334,000,000

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating expenses:
Research and development	$ 4,756,468	$ 2,654,501
General and administrative	8,138,117	8,499,304
Depreciation	11,698	10,475
Total operating expenses	12,906,283	11,164,280
Loss from operations	(12,906,283)	(11,164,280)
Other income (expense):
Gain (loss) on change in fair value of derivatives	210,465	(422,908)
Interest income	75	1
Loss before income taxes	(12,695,743)	(11,587,187)
Income taxes (benefit)	0	0
Net loss	(12,695,743)	(11,587,187)
Preferred stock dividend	(119,877)	(110,023)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (12,815,620)	$ (11,697,210)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.50)	$ (0.60)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	25,550,686	19,490,767

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Embedded Derivative Financial Instruments [Member]Additional Paid-in Capital [Member]Derivative and Warrant Liability [Member]	Embedded Derivative Financial Instruments [Member]Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Embedded Derivative Financial Instruments [Member]Derivative and Warrant Liability [Member]	Embedded Derivative Financial Instruments [Member]Series D Preferred Stock [Member]	Embedded Derivative Financial Instruments [Member]Series C Preferred Stock [Member]	Embedded Derivative Financial Instruments [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Common Stock [Member]Settlement of Preferred Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Settlement of Preferred Stock [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Subscription [Member]	Retained Earnings [Member]	Settlement of Preferred Stock [Member]Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Total
Balance at Dec. 31, 2015							$ 0			$ 16,826			$ 29,314,399	$ 0	$ (32,241,856)			$ (2,910,631)
Balance (in Shares) at Dec. 31, 2015							0			16,825,703
Sale of common stock										$ 3,798			5,222,570					$ 5,226,368
Sale of common stock (in Shares)										3,798,417								3,798,417
Common stock issued for services										$ 1,335			2,469,715					$ 2,471,050
Common stock issued for services (in Shares)										1,335,000
Common stock issued upon conversion of preferred stock and accrued dividends								$ 58	$ 267		$ 90,365	$ 400,733				$ 90,423	$ 401,000
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)								58,185	267,334
Reclassify initial fair value of derivative and warrant liability of Series D preferred stock and warrants at issuance																		0
Fair value reclassification		$ 103,096			$ 103,096	$ 103,096
Stock based compensation										$ 304			3,528,396					3,528,700
Stock based compensation (in Shares)										303,545
Preferred Stock dividend													(110,023)					(110,023)
Net loss															(11,587,187)			(11,587,187)
Balance at Dec. 31, 2016							$ 0			$ 22,588			41,019,251	0	(43,829,043)			$ (2,787,204)
Balance (in Shares) at Dec. 31, 2016							0			22,588,184								22,588,184
Sale of common stock										$ 4,131			6,007,098					$ 6,011,229
Sale of common stock (in Shares)										4,131,536								4,131,536
Sale of Series D preferred stock							$ 1						1,929,959					$ 1,929,960
Sale of Series D preferred stock (in Shares)							1,334
Common stock issued for services										$ 2,272			3,384,345					3,386,617
Common stock issued for services (in Shares)										2,271,788
Common stock issued upon conversion of preferred stock and accrued dividends								$ 24	$ 57		$ 31,844	$ 84,943				$ 31,868	$ 85,000
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)								24,021	56,669
Common stock received and canceled in connection with short term swing profit reimbursement										$ (11)			11
Common stock received and canceled in connection with short term swing profit reimbursement (in Shares)										(10,744)
Common stock subscription received														29,985				29,985
Reclassify initial fair value of derivative and warrant liability of Series D preferred stock and warrants at issuance	$ (1,049,216)		$ (1,049,216)	$ 397,162		0												1,049,216
Fair value reclassification		$ 20,757			$ 20,757	$ 20,757
Fair value of warrant issued to acquire research and development													543,927					543,927
Stock based compensation										$ 260			1,362,593					1,362,853
Stock based compensation (in Shares)										259,750
Preferred Stock dividend													(119,877)					(119,877)
Net loss															(12,695,743)			(12,695,743)
Balance at Dec. 31, 2017							$ 1			$ 29,321			$ 53,215,635	$ 29,985	$ (56,524,786)			$ (3,249,844)
Balance (in Shares) at Dec. 31, 2017							1,334			29,321,204								29,321,204

STATEMENT OF STOCKHOLDERS' EQU6

STATEMENT OF STOCKHOLDERS' EQUITY (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Common stock issued	$ 1.53
Common Stock [Member]
Conversion of preferred stock at	1.50
Common stock issued	$ 1.37
Common Stock [Member] | Series C Preferred Stock [Member]
Conversion of preferred stock at		$ 1.50
Common Stock [Member] | Settlement of Preferred Stock [Member] | Series C Preferred Stock [Member]
Common stock issued		$ 1.55

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,695,743)	$ (11,587,187)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	11,698	10,475
Amortization of debt discount	3,210	0
Change in derivative liabilities	(210,465)	422,908
Equity based compensation	4,749,470	5,999,750
Fair value of issued warrant to acquire research and development	543,927	0
Changes in operating assets and liabilities:
Prepaid expenses	17,325	(102,955)
Payment of long term deposit	10,528	0
Accounts payable	102,338	149,661
Deferred rent payable	(2,342)	(104)
Net cash used in operating activities	(7,470,054)	(5,107,452)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(9,436)	(16,255)
Net cash used in investing activity	(9,436)	(16,255)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	6,011,229	5,226,368
Proceeds from sale of Series D preferred stock	1,929,960	0
Proceeds from common stock subscription	29,985	0
Net cash provided by financing activities	7,971,174	5,226,368
Net increase in cash and cash equivalents	491,684	102,661
Cash and cash equivalents, beginning of the period	1,055,895	953,234
Cash and cash equivalents, end of the period	1,547,579	1,055,895
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	0	0
Cash paid during the period for income taxes	0	0
Non cash investing and financing activities:
Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock	1,049,216	0
Series C Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	116,868	491,423
Embedded Derivative Financial Instruments [Member]
Adjustments to reconcile net loss to cash used in operating activities:
Change in derivative liabilities	20,583
Non cash investing and financing activities:
Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock	0
Reclassify derivative liability to equity	20,757	103,096
Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]
Non cash investing and financing activities:
Reclassify derivative liability to equity	$ 20,757	$ 103,096

NOTE 1 - SUMMARY OF SIGNIFICANT

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows. Business and organization BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At December 31, 2017 and 2016, deposits in excess of FDIC limits were $1,297,579 and $805,895, respectively. Prepaid Expenses Prepaid expenses are comprised of vendor deposits of $100,000, prepaid insurance and operating expense prepayments. Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Long-Lived Assets The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2017 and 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7). Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $4,756,468 and $2,654,501 for the year ended December 31, 2017 and 2016, respectively. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as non-current. Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of December 31, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: 2017 2016 Series C convertible preferred stock 656,667 713,333 Series D convertible preferred stock 1,334,000 - Options to purchase common stock 8,510,319 8,245,190 Warrants to purchase common stock 12,789,086 9,128,189 Totals 23,290,072 18,086,712 Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested. Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement On November 3, 2017, in connection with the Company’s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017. Beginning on April 6, 2017, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of December 31, 2017, the Company had cash of $1,547,579 and working capital deficit (current liabilities in excess of current assets) of $2,300,644 principally due to the inclusion of non-cash derivative and warrant liabilities recorded in current liabilities. In addition, the Company raised $6,041,214 through the sale of common stock and warrants (See Note 8) and $1,929,960 through the sale of Series D preferred stock and warrants (Note 6) in 2017. Subsequent to December 31, 2017, the Company raised $1,500,000 from the sale of Series E preferred stock and warrants and $270,000 from the sale of common stock (Note 13). As of December 31, 2017, excluding the derivative and warrant liabilities, the Company’s working capital would have been $743,518. During the year ended December 31, 2017, the Company used net cash in operating activities of $7,470,054. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 6 months. The Company’s primary source of operating funds since inception has been cash proceeds from private placements of common and preferred stock. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has stockholders’ deficiencies at December 31, 2017 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 3 - RELATED PARTY TRANSACT

NOTE 3 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 3 – RELATED PARTY TRANSACTIONS The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception in February 2009. No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. As of December 31, 2017 and 2016, all advances had been repaid. Accrued expenses related primarily to travel reimbursements due related parties as of December 31, 2017 and 2016 was $27,375 and $15,755, respectively. On May 4, 2016, Mr. Londoner and Mr. Chaussy were granted 250,000 and 200,000 shares of common stock at a cost basis of $1.93 per share for their 2016 performance, respectively. The granted shares vested immediately. On December 8, 2016, Mr. Londoner and Mr. O’Donnell each were granted 41,500 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted shares vested immediately and were subsequently issued in 2017. On December 8, 2016 Mr. Cash and Mr. Tanaka each were granted 20,875 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted shares vested immediately and were subsequently issued in 2017. On December 22, 2016 Mr. Zeldis and Mr. Weild each were granted options to purchase 50,000 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted options vested as of December 22, 2016 and are exercisable for a ten year term. On December 22, 2016 Mr. Gallagher and Mr. Foley each were granted options to purchase 25,000 shares of common stock at a cost basis of $1.36 per share for their 2016 performance. The granted options vested as of December 22, 2016 and are exercisable for a ten year term. On April 1, 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from Mr. Londoner. On June 16, 2017 Mr. Cash was granted 100,000 shares of common stock at a cost basis of $1.37 per share in connection with his severance settlement. The granted shares vested immediately. On November 8, 2017, Mr. Londoner, Mr. Chaussy and Mr. O’Donnell were granted 450,000, 250,000 and 200,000 shares of common stock at a cost basis of $1.52 per share for their 2017 performance, respectively. The granted shares vested immediately. On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors, the Company entered into a Master Services Agreement (the “Agreement”) with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 300,000 of the Company’s common stock at an exercise of $1.50 per share of common stock, of which 150,000 options vest immediately and 150,000 options are performance conditioned. Mr. Filler is the general counsel and partner of Sherpa. On November 9, 2017, Mr. Londoner, Mr. O’Donnell and Mr. Wield, as members of the board of directors, were granted each 50,000 shares of common stock at a cost basis of $1.49 per share for their 2017 board and committee service. The granted shares vested immediately. On November 9, 2017, Mr. Tanaka, Mr. Filler and Mr. Foley, as members of the board of directors, were granted each 30,000 shares of common stock at a cost basis of $1.49 per share for their 2017 board service. The granted shares vested immediately. On December 22, 2017 Mr. Gallagher and Mr. Fischer were granted options to purchase 39,926 and 65,972 shares of common stock at a cost basis of $1.37 per share for their 2017 board service. The granted options vested as of December 22, 2017 and are exercisable for a ten year term.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2017 and 2016 is summarized as follows: 2017 2016 Computer equipment $ 87,059 $ 84,704 Furniture and fixtures 12,975 10,117 Subtotal 100,034 94,821 Less accumulated depreciation (81,318 ) (70,633 ) Property and equipment, net $ 18,716 $ 24,188 During the year ended December 31, 2017, the Company distributed equipment with a book value of $3,210 to a prior employee in connection with a settlement agreement. Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $11,698 and $10,475 for the years ended December 31, 2017 and 2016, respectively.

NOTE 5 - ACCOUNTS PAYABLE AND A

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at December 31, 2017 and 2016 consist of the following: 2017 2016 Accrued accounting and legal $ 93,595 $ 120,464 Accrued reimbursements 2,600 43,116 Accrued consulting 109,059 1,192 Accrued research and development expenses 246,030 181,884 Accrued office and other 7,912 10,202 Deferred rent 569 2,912 Accrued settlement related to arbitration 13,333 13,333 $ 473,098 $ 373,103

NOTE 6 - SERIES C 9% CONVERTIBL

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 6 – SERIES C 9% CONVERTIBLE PREFERRED STOCK Series C 9% Convertible Preferred Stock On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including: ● incur additional indebtedness; ● permit liens on assets; ● repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock; ● pay cash dividends to our stockholders; and ● engage in transactions with affiliates. Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection. In the event that: (i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered, (ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered, (iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered, (v) we are party to a change of control transaction, (vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent, (vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days, The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%. The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C Preferred Stock outside of equity. In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date. The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301. In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital. The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671), the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense. At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required. There was no established market for the Company’s common stock. As described in Note 7, as of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities. Issuances: During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C Preferred Stock. During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C Preferred Stock for net proceeds of $1,814,910. On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C Preferred Stock for net proceeds of $450,000. 2017 and 2016 conversions: In February 2016, the Company issued an aggregate of 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends. In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends. In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2017, the Company issued an aggregate of 60,846 shares of its common stock in exchange for 65 shares of the Company’s Series C Preferred Stock and accrued dividends. In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends. For the year ended December 31, 2017, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $20,757 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.74% to 1.06%, a dividend yield of 0%, and volatility of 151% to 166%. Series C Preferred Stock issued and outstanding totaled 985 and 1,070 as of December 31, 2017 and 2016, respectively. As of December 31, 2017 and 2016, the Company has accrued $419,283 and $359,891 dividends payable on the Series C Preferred Stock. Registration Rights Agreement In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount. Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events. The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014. At December 31, 2017 and 2016, the Company estimated the liability at $-0-.

NOTE 7 - WARRANT AND DERIVATIVE

NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 7 – WARRANT AND DERIVATIVE LIABILITIES Series C 9% Convertible Preferred Stock and related warrants At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 6) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required. There was no established market for the Company’s common stock. As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively. The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141%. Series D Convertible Preferred Stock and related warrants At issuance, the Company determined that certain anti-dilutive provisions embedded in the Series D Preferred Stock and related warrants (see Note 8) met the defined criteria of a derivative and accordingly, reclassified from equity to liability the determined fair value of the embedded reset provisions of the Series D Preferred Stock and warrants of $397,162 and $652,054, respectively. The Company valued the reset provisions of the Series D Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 1.74%, a dividend yield of 0%, and volatility of 130%. At December 31, 2017, the Company marked to market the fair value of the reset provisions of the Preferred Stock and warrants and determined fair values of $685,922 and $2,358,240, respectively. The Company recorded a gain from change in fair value of derivatives of $210,465 for year ended December 31, 2017. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 1.43 to 3.36 years, a risk free interest rate of 1.39% to 1.89%, a dividend yield of 0%, and volatility of 131%

NOTE 8 - STOCKHOLDER EQUITY

NOTE 8 - STOCKHOLDER EQUITY	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – STOCKHOLDER EQUITY Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of December 31, 2017 and 2016, the Company has authorized 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock and (in 2017) 1,400 shares of Series D Preferred Stock. As of December 31, 2017 and 2016, there were no outstanding shares of Series A and Series B preferred stock. Series C Preferred Stock In February 2016, the Company issued 54,859 shares of its common stock in exchange for 75 shares of the Company’s Series C Preferred Stock and accrued dividends. In May 2016, the Company issued an aggregate of 197,713 shares of its common stock in exchange for 236 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2016, the Company issued an aggregate of 54,759 shares of its common stock in exchange for 70 shares of the Company’s Series C Preferred Stock and accrued dividends. In December 2016, the Company issued an aggregate of 18,188 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2017, the Company issued 60,846 shares of its common stock in exchange for 65 shares of the Company’s Series C Preferred Stock and accrued dividends. In July 2017, the Company issued an aggregate of 19,844 shares of its common stock in exchange for 20 shares of the Company’s Series C Preferred Stock and accrued dividends. Cumulatively from January 1, 2017 to December 31, 2017, the Company exchanged 85 shares of the Company’s Series C Preferred Stock and dividends with a recorded value of $116,868 for 80,690 shares of common stock. As of December 31, 2017 and 2016, the Company has 985 and 1,070 Series C Preferred Stock issued and outstanding. Series D Preferred Stock On November 3, 2017, the Board of Directors authorized the issuance of up to 1,400 shares of Series D Convertible Preferred Stock (the “Series D Preferred Stock”) and accordingly , the Company filed the Certificate of Designations for the Series D Preferred Stock with the Secretary of State of the State of Delaware. Pursuant to such Certificate of Designations, in the event of the Company’s liquidation or winding up of its affairs, the holders of Preferred Shares will be entitled to a liquidation preference of the stated value per Preferred Share of $1,500 (the “Stated Value”) plus any accrued but unpaid dividends or any other fees due the holder. A holder of Preferred Shares is entitled at any time to convert any whole or partial number of shares of Preferred Shares into shares of Common Stock determined by dividing the Stated Value of the Preferred Shares being converted by the conversion price of $1.50 per share (the “Conversion Price”). The Conversion Price is subject to “full ratchet” anti-dilution price protection upon the issuance of equity or equity-linked securities at a price lower than the Conversion Price as well as other customary anti-dilution protection. A holder of the Preferred Shares shall be entitled to receive cumulative dividends at the rate per Preferred Share (as a percentage of the Stated Value per Preferred Share) of 9% per annum, with respect to the Series D Preferred Stock on each date that such Holder converts Preferred Shares into Common Stock (with respect only to Preferred Shares being converted). The Company may pay such dividends, at its option, in cash, Common Stock or a combination thereof. Payment of dividends in shares of Common Stock is subject to the satisfaction of certain equity conditions set forth in the Certificate of Designations. Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company’s option, Common Stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion. On November 3, 2017, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold an aggregate of 1,334 shares (the “Preferred Shares”) of its Series D Preferred Stock, par value $0.001 per share, and Class A Warrants to purchase an aggregate of 667,000 shares of the Company’s common stock, par value $0.001 per share at an exercise price of $1.75 per share (the “Class A Warrants”), in exchange for aggregate net cash proceeds of $1,929,960, net of expenses of $70,040. Contemporaneously with the entry into the Purchase Agreement, the Company and the Purchasers agreed to exchange outstanding warrants to purchase 780,506 shares of the Common Stock at an exercise price of $1.50 per share for new Class B Warrants to purchase an equal number of shares of common stock at the same exercise price (the “Class B Warrants”). Class A Warrants are exercisable immediately and expire on May 3, 2021, and have an exercise price of $1.75 per share. The Class B Warrants are exercisable immediately and expire on November 3, 2020, and have an exercise price of $1.50. The Class A Warrants and Class B Warrants otherwise have similar terms, including, a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock at a per share price lower than the applicable exercise price then in effect. On November 6, 2017, the terms of the Class A Warrants automatically adjusted due to the full-ratchet anti-dilution protection provision contained in such warrants. As a result of the adjustment, the exercise price applicable to the Class A Warrants decreased to $1.50 per share from $1.75 per share, and the number of shares issuable under each warrant was increased such that the aggregate exercise price payable under such warrant, after taking into account the decrease in the exercise price, is equal to the aggregate exercise price prior to such adjustment. An additional 111,167 shares of common stock may be issued upon exercise of the Class A Warrants due to the adjustment. In connection with the Company’s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017. As of December 31, 2017, the Company has 1,334 Series D Preferred Stock issued and outstanding and has accrued $28,618 dividends payable on the Series D Preferred Stock. Common stock On November 18, 2016 at the Special Meeting, the stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 200,000,000 shares (the “ Certificate Amendment As of December 31, 2017 and 2016, the Company had 29,321,204 and 22,588,184 shares issued and outstanding, respectively. During the year ended December 31, 2016, the Company issued an aggregate of 790,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $1,419,200 ($1.80 average per share). During the year ended December 31, 2016, the Company issued an aggregate of 545,000 shares of common stock for services rendered totaling $1,051,850 ($1.93 average per share). During the year ended December 31, 2016, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 3,798,417 shares of common stock and 2,040,504 warrants for aggregate proceeds of $5,226,368, net of $490,543 in expenses. During the year ended December 31, 2016, the Company issued 220,000 shares of common stock as vested previously issued restricted stock units During the year ended December 31, 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan. The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions: dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84. During the year ended December 31, 2017, the Company issued an aggregate of 1,825,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $2,705,250 ($1.48 average per share). During the year ended December 31, 2017, the Company issued an aggregate of 446,788 shares of its common stock for services totaling $681,367 ($1.53 per share). During the year ended December 31, 2017, the Company issued an aggregate of 135,000 and 124,750 shares of its common stock for vested restricted stock units and stock based compensation previously accrued in 2016. During the year ended December 31, 2017, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 4,131,536 shares of common stock and 2,246,300 warrants for aggregate proceeds of $6,011,229, net of $186,075 in expenses. In April 2017, the Company received and canceled 10,744 shares of its common stock as payment for short-swing profit pursuant to Section 16(b) of the U.S. Securities Exchange Act of 1934, as amended from an officer and member of the Company’s Board of Directors. In connection with the securities purchase agreements described above, the Company entered into registration rights agreements with the purchasers in such private placements pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued such investors. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placement and issuable upon the exercise of the warrants within 45 days of the termination date of such private placement and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and within 180 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 180 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that the Company will not be required to make any payments any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that the Company will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that the Company is unable to register due to limits imposed by the Securities and Exchange Commission’s interpretation of Rule 415 under the Securities Act of 1933, as amended. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreements shall be 3% to 6% of the aggregate purchase price paid by the purchasers and (iii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount. Pursuant to the registration rights agreements, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events. The Company filed registration statements, which was declared effective to satisfy the requirements under the registration rights agreements with the purchasers of its common stock and warrants prior to April 6, 2017. The final closing under the April 6, 2017 Private Placement occurred on December 31, 2017. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017.

NOTE 9 - OPTIONS, RESTRICTED ST

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Options On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 15,186,123 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. The Company reserved 227,388 shares of its common stock for future issuance under the terms of the Plan. During the year ended December 31, 2016, the Company granted an aggregate of 750,000, net of 100,000 canceled, options to officers, directors and key consultants. During the year ended December 31, 2016, the Company granted an aggregate of 723,545 stock grants to officers, employees and key consultants under the plan. See Note 8. During the year ended December 31, 2017, the Company granted an aggregate of 1,680,898 options to officers, directors and key consultants. During the year ended December 31, 2017, the Company granted an aggregate of 2,009,750 stock grants to officers, employees and key consultants under the plan. See Note 8. The following table presents information related to stock options at December 31, 2017: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 3,825,540 6.8 $ 2,662,707 2.01-3.00 4,384,779 3.7 4,384,779 3.01-4.00 300,000 7.3 300,000 8,510,319 5.2 7,347,486 A summary of the stock option activity and related information for the 2012 Plan for the years ended December 31, 2017 and 2016 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2016 7,780,190 $ 2.30 6.4 $ - Grants 905,000 1.71 10.0 $ - Exercised - - - Canceled (440,000 ) 2.24 - Outstanding at December 31, 2016 8,245,190 $ 2.24 5.7 $ - Grants 1,680,898 1.50 10.0 $ - Exercised - Canceled (1,415,769 ) $ 2.17 Outstanding at December 31, 2017 8,510,319 $ 2.11 5.2 $ 27,045 Exercisable at December 31, 2017 7,347,486 $ 2.19 4.8 $ 25,394 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.44 as of December 31, 2017, which would have been received by the option holders had those option holders exercised their options as of that date. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the years ended December 31, 2017 and 2016 was estimated using the Black-Scholes pricing model. On May 18, 2016, the Company granted an aggregate of 685,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.84 per share for a term of ten years, vesting immediately. In September 2016, the Company issued 83,545 shares of its common stock in exchange for 100,000 common stock options previously issued in May 2016 under the terms of its 2012 Equity Plan. The equality of the fair value was determined using the Black Scholes option pricing model with the following assumptions: dividend yield: 0%; volatility: 122.82%; risk free rate: 1.08%, term: 5 years and fair value of the Company’s common stock: $1.84. On August 24, 2016, the Company granted 65,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.33 per share for a term of ten years with 12,500 vesting immediately; 37,500 vesting quarterly beginning September 14, 2016 through December 14, 2017 and 15,000 performance contingent. On December 22, 2016, the Company granted an aggregate of 150,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.36 per share for a term of ten years with vesting immediately. On December 29, 2016, the Company granted 5,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.35 per share for a term of ten years with vesting immediately. The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2016: Risk-free interest rate 1.08% - 2.04 % Dividend yield 0 % Stock price volatility 109.3% to 122.82 % Expected life 5 – 10 years Weighted average grant date fair value $ 1.47 On February 8, 2017, the Company granted an aggregate of 130,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.55 per share for a term of ten years with vesting immediately. On November 8, 2017, the Company granted 200,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.57 per share for a term of ten years with 50,000 vesting immediately and 50,000 vesting each anniversary through November 8, 2020. On November 8, 2017, the Company granted 475,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.57 per share for a term of ten years with 237,500 vesting immediately and 237,500 at one year anniversary. On November 24, 2017, the Company granted 50,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.45 per share for a term of ten years, vesting immediately. On November 24, 2017, the Company granted 420,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.45 per share for a term of ten years with 120,000 vesting immediately; 50,000 vesting on two year anniversary and 250,000 performance contingent. On November 24, 2017, the Company granted 300,000 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.50 per share for a term of ten years with 150,000 vesting immediately and 150,000 performance contingent. On December 22, 2017, the Company granted 105,898 options to purchase the Company stock in connection with the services rendered at the exercise price of $1.37 per share for a term of ten years, vesting immediately. The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2017: Risk-free interest rate 2.01% - 2.34 % Dividend yield 0 % Stock price volatility 95.72% to 107.17 % Expected life 5 – 10 years Weighted average grant date fair value $ 1.17 The fair value of all options vesting during the year ended December 31, 2017 and 2016 of $1,269,591 and $2,801,948, respectively, was charged to current period operations. Unrecognized compensation expense of $979,812 and $310,817 at December 31, 2017 and 2016, respectively, will be expensed in future periods. Restricted Stock The following table summarizes the restricted stock activity for the two years ended December 31, 2017: Restricted shares issued as of January 1, 2016 175,000 Granted 180,000 Vested (220,000 ) Total restricted shares issued as of December 31, 2016 135,000 Granted - Vested (135,000 ) Vested restricted shares as of December 31, 2017 - Unvested restricted shares as of December 31, 2017 - On September 7, 2016, the Company granted 180,000 restricted stock units (“RSU”) to a consultant vesting monthly over one year beginning October 7, 2016. Stock based compensation expense related to restricted stock grants was $93,261 and $213,174 for the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017, the stock-based compensation relating to restricted stock of $-0- remains unamortized. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2017: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 8,667,440 February 2018 to May 2021 $ 1.84 35,076 January 2020 $ 1.95 1,689,026 October 2018 to September 2019 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 12,789,086 On February 9, 2016, the Company issued 25,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on February 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 6,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring February 9, 2019 for placement agent services. On March 9, 2016, the Company issued an aggregate of 100,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on March 9, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 12,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring March 9, 2019 for placement agent services. On April 1, 2016, the Company issued an aggregate of 100,327 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 1, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 18,040 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 1, 2019 for placement agent services. On April 19, 2016, the Company issued an aggregate of 84,980 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 19, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued 17,996 warrants to purchase the Company’s common stock at $1.50 per share, expiring April 19, 2019 for placement agent services. On April 29, 2016, the Company issued an aggregate of 567,866 warrants to purchase the Company’s common stock at $1.95 per share, expiring on April 29, 2019, in connection with the sale of the Company’s common stock. In addition, the Company issued an aggregate of 96,256 warrants to purchase the Company’s common stock at $1.50 per share, expiring between October 23, 2018 through April 29, 2019 for placement agent services. On June 1, 2016, the Company issued an aggregate of 38,572 warrants to purchase the Company’s common stock at $2.10 per share, expiring on June 1, 2019, in connection with the sale of the Company’s common stock. On August 30, 2016, the Company issued an aggregate of 152,513 warrants to purchase the Company’s common stock at $1.95 per share, expiring on August 30, 2019, in connection with the sale of the Company’s common stock. On September 19, 2016, the Company issued an aggregate of 35,000 warrants to purchase the Company’s common stock at $1.95 per share, expiring on September 19, 2019, in connection with the sale of the Company’s common stock. On October 28, 2016, the Company issued an aggregate of 173,284 warrants to purchase the Company’s common stock at $1.50 per share, expiring on October 28, 2019, in connection with the sale of the Company’s common stock. On November 23, 2016, the Company issued an aggregate of 50,002 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 23, 2019, in connection with the sale of the Company’s common stock On December 16, 2016, the Company issued an aggregate of 456,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 16, 2019, in connection with the sale of the Company’s common stock On December 22, 2016, the Company issued an aggregate of 115,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 22, 2019, in connection with the sale of the Company’s common stock On February 9, 2017, the Company exchanged 38,572 warrants with an exercise price of $2.10 with 45,001 warrants with an exercise price of $1.50, all other terms and conditions the same, to 2016 investors to adjust offered terms in connection with the Company’s equity raise with other investors. On February 10, 2017, the Company issued an aggregate of 300,628 warrants to purchase the Company’s common stock at $1.50 per share, expiring on February 10, 2020, in connection with the sale of the Company’s common stock. On March 10, 2017, the Company issued an aggregate of 197,159 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 10, 2020, in connection with the sale of the Company’s common stock. On March 15, 2017, the Company issued 630,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 15, 2020, to Mayo Foundation in connection with a know-how licensing agreement (See Note 10). The fair value of the of the issued warrants of $543,927, determined using the Black-Scholes option model with an estimated volatility of 105.22%, risk free rate of 1.599%, dividend yield of -0- and fair value of the Company’s common stock of $1.37, was charged to current period operations as acquired research and development. On March 31, 2017, the Company issued an aggregate of 157,250 warrants to purchase the Company’s common stock at $1.50 per share, expiring on March 31, 2020, in connection with the sale of the Company’s common stock. On April 6, 2017, the Company issued an aggregate of 288,300 warrants to purchase the Company’s common stock at $1.50 per share, expiring on April 6, 2020, in connection with the sale of the Company’s common stock. On May 5, 2017, the Company issued an aggregate of 6,667 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 5, 2020, in connection with the sale of the Company’s common stock. On May 17, 2017, the Company issued an aggregate of 186,957 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 17, 2020, for placement agent services in connection with the sale of the Company’s common stock. On June 20, 2017, the Company issued 10,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on June 20, 2020, in connection with the sale of the Company’s common stock. On June 30, 2017, the Company issued an aggregate of 108,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on June 30, 2020, in connection with the sale of the Company’s common stock. On July 13, 2017, the Company issued an aggregate of 133,501 warrants to purchase the Company’s common stock at $1.50 per share, expiring on July 13, 2020, in connection with the sale of the Company’s common stock. On August 18, 2017, the Company issued an aggregate of 175,500 warrants to purchase the Company’s common stock at $1.50 per share, expiring on August 18, 2020, in connection with the sale of the Company’s common stock. On September 18, 2017, the Company issued an aggregate of 51,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on September 18, 2020, in connection with the sale of the Company’s common stock. On October 11, 2017, the Company issued an aggregate of 193,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on October 11, 2020, in connection with the sale of the Company’s common stock. On November 3, 2017, the Company issued an aggregate of 667,000 warrants to purchase the Company’s common stock at $1.50 per share, expiring on May 3, 2021, in connection with the sale of the Company’s Series D preferred stock. The warrants contain certain anti-dilutive provisions (see Note 8). On November 3, 2017, the Company issued an aggregate of 780,506 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 3, 2020 in exchange for the return and cancellation of previous issued 780,505 warrants. The transaction was in connection with the sale of the Series D preferred stock. Both the issued and canceled warrants contain certain anti-dilutive provisions (see Note 8). On November 6, 2017, the Company issued an aggregate of 206,668 warrants to purchase the Company’s common stock at $1.50 per share, expiring on November 6, 2020, in connection with the sale of the Company’s common stock. On November 6, 2017, due to certain anti-dilutive provisions embedded in the November 3, 2017 warrants issued in connection with the sale of Series D preferred stock (see above), exercise price of the previously issued 667,000 warrants were reset to $1.50 and an additional 111,167 warrants were issued with an exercise price of $1.50 per share, expiring May 3, 2021. On December 29, 2017, the Company issued an aggregate of 230,334 warrants to purchase the Company’s common stock at $1.50 per share, expiring on December 29, 2020, in connection with the sale of the Company’s common stock. Stock based compensation related to warrants issued for services was $0 and $56,931 for the years ended December 31, 2017 and 2016, respectively. A summary of the warrant activity for the years ended December 31, 2017 and 2016 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2016 7,078,685 $ 2.02 3.0 497,933 Grants 2,049,504 $ 1.74 2.5 - Exercised - $ - - Canceled - $ - - Outstanding at December 31, 2016 9,128,189 $ 1.96 2.1 $ 494,099 Grants 4,479,974 1.50 3.0 - Exercised - Canceled (819,077 ) $ 1.50 Outstanding at December 31, 2017 12,789,086 $ 1.82 1.7 $ 551,636 Vested and expected to vest at December 31, 2017 12,789,086 $ 1.82 1.7 $ 551,636 Exercisable at December 31, 2017 12,789,086 $ 1.82 1.7 $ 551,636 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $1.44 as of December 31, 2017, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

NOTE 10 - FAIR VALUE MEASUREMEN

NOTE 10 - FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 10 – FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of December 31, 2017 and 2016, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 7. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company. As of December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges. The derivative and warrant liability as of December 31, 2017, in the amount of $685,922 and $2,358,240, respectively, has a level 3 classification. The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of December 31, 2017: Warrant Liability Derivative Balance, December 31, 2015 $ 1,621,199 $ 285,157 Total (gains) losses Transfers out due to conversion of Series C Preferred Stock - (103,096 ) Mark to market to December 31, 2016 316,035 106,873 Balance, December 31, 2016 1,937,234 288,934 Initial fair value of derivative at date of issuance of Series D Preferred Stock - 397,162 Initial fair value of warrant liability at date of issuance 652,054 - Transfers out due to conversion of Series C Preferred Stock - (20,757 ) Mark to market to December 31, 2017 (231,048 ) 20,583 Balance, December 31, 2017 2,358,240 685,922 Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016 $ 231,048 $ (20,583 ) Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases, therefore decreasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

NOTE 11 - COMMITMENTS AND CONTI

NOTE 11 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 – COMMITMENTS AND CONTINGENCIES Operating leases On February 8, 2017, the Company entered into a lease amendment agreement, whereby the Company agreed to extend the lease for office space in Los Angeles, California, commencing September 1, 2017 and expiring on August 31, 2019. In connection with the lease, the Company is obligated to lease parking spaces at an aggregate approximate cost of $978 per month. In addition, the Company entered into a lease for storage space with the Los Angeles, California building commencing on December 1, 2017 and expiring on August 31, 2019. Future minimum lease payments under these three agreements are as follows: Year Ending December 31, 2018 $ 112,994 2019 76,995 $ 189,989 Licensing agreements On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement expires in ten years from the effective date. The Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined. In consideration, the Company issued 630,000 warrants to acquire the Company’s common stock at an exercise price of $1.50, expiring on March 15, 2020. Employment agreements On July 14, 2014, the Company’s Board of Directors (the “Board”) increased the size of the Board to eight members and appointed Gregory D. Cash and Patrick J. Gallagher as members of the Board, effective as of July 15, 2014, to serve for a term expiring at the Company’s 2015 annual meeting of stockholders. In addition, the Board appointed Mr. Cash to serve as the Company’s president and chief executive officer. In connection with the appointment of Mr. Cash, on July 15, 2014 (the “Effective Date”), the Company entered into an employment agreement with Mr. Cash (the “Employment Agreement”). The Employment Agreement has an initial term of three years that expires on July 15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a “Qualified Financing”), Mr. Cash’s annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date. In accordance with the Employment Agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock option to purchase 1,265,769 shares of the Company’s common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price of $2.21, which was the fair market value of the Company’s common stock on the date of grant, and a term that expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days. Effective July 15, 2017, the Company elected not to continue under the above described agreement and accordingly terminated employment with Mr. Cash. As of December 31, 2017, there are no outstanding employment agreements. Litigation The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of December 31, 2017.

NOTE 12 - INCOME TAXES

NOTE 12 - INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 12 – INCOME TAXES At December 31, 2017, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $24,000,000, expiring in the year 2036, that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company’s ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits. During the year ended December 31, 2017, the Company has increased the valuation allowance from $5,500,000 to $8,200,000.We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax position that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating to open income tax returns that were considered to be uncertain. The Company is required to file income tax returns in the U.S. Federal various State jurisdictions. The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2013. The effective rate differs from the statutory rate of 34% for due to the following: 2017 2016 Statutory rate on pre-tax book loss (34.00 )% (34.00 )% (Gain) loss on change in fair value of derivatives (0.56 )% 1.24 % Stock based compensation 12.72 % 17.6 % Fair value of warrant to acquire research and development 1.46 % 0.00 % Other 0.09 % 0.09 % Valuation allowance 20.29 % 15.07 % 0.00 % 0.00 % The Company’s deferred taxes as of December 31, 2017 and 2016 consist of the following: 2017 2016 Non-Current deferred tax asset: Net operating loss carry-forwards $ 8,200,000 $ 5,500,000 Valuation allowance (8,200,000 ) (5,500,000 ) Net non-current deferred tax asset $ - $ -

NOTE 13 - SUBSEQUENT EVENTS

NOTE 13 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 – SUBSEQUENT EVENTS Adoption of Accounting Standards In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company anticipates early adoption of this pronouncement effective January 1, 2018. As such, the impact would the reclassification of the December 31, 2017 fair values of our warrant and derivative liabilities to equity. On January 1, 2018, the Company adopted ASU 2017-11 and according reclassified the fair value of the reset provisions embedded in previously issued Series C Preferred stock, Series D Preferred stock and certain warrants with embedded anti-dilutive provisions from liability to equity in aggregate of $3,044,162. Series E Preferred Stock Issuance On February 16, 2018, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,000 shares (the “Preferred Shares”) of its Series E Preferred Stock, par value $0.001 per share, and warrants to purchase an aggregate of 500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $1.75 per share (the “Warrants”), in exchange for aggregate consideration of $1,500,000 (the “Transaction”). The sale of the Preferred Shares and Warrants were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”) provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act. The Purchase Agreement contains representations and warranties of the Company and the Investors that are typical for transactions of this type. The Purchase Agreement also contains covenants on the part of the Company that are typical for transactions of this type. For a period of twelve months after the closing date of Transaction, the Investors are entitled to a right of first refusal (the “ROFR”) with respect to subsequent sales of securities by the Company (other than with respect to issuances of Excluded Securities (as defined in the Purchase Agreement)) Pursuant to the ROFR, each Investor will have the opportunity to elect to purchase its pro rata portion of thirty percent (30%) of any securities being offered by the Company in the subsequent offering. In connection with the entry into the Purchase Agreement, the Investors and the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 90 days of the closing of the transactions contemplated by the Purchase Agreement (the “Filing Date”) covering the resale of (a) all shares of Common Stock Issuable upon conversion of the Preferred Shares, (b) all shares of Common Stock issuable upon exercise of the Warrants, (c) all other shares of Common Stock issued pursuant to any transaction documents which have been, or which may, from time to time be issued or become issuable to the Investors under the Transaction Documents (without regard to any limitation or restriction on purchases), and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event (“Registrable Securities”), not then registered. The Company will use its reasonable best efforts to keep the registrations statement effective pursuant to Rule 415 under the Securities Act until the earlier of (i) the date on which the Investors shall have sold all the Registrable Securities covered therby and (ii) that date that all Registrable Securities may be sold pursuant to Rule 144 without any public information requirement or volume or manner of sale limitations. The Warrants are exercisable immediately and expire on August 16, 2021, and have an exercise price of $1.75 per share. The Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect. In connection with its entry into the Purchase Agreement, on February 14, 2018, the Company entered into a consent agreement (the “Consent”) with the holders of the Company’s Series D Convertible Preferred Stock (the “Series D Holders”). Pursuant to the Consent, the Series D Holders consented to the Transaction and are entitled at any time on or before April 17, 2018, to elect to receive the more favorable terms of the Transaction. In consideration for their entry into the Consent, the Company issued to the Series D Holders warrants to purchase up to an aggregate of 100,000 shares of Common Stock (the “Consent Warrants”). The Consent Warrants are exercisable immediately and expire on February 14, 2021, and have an exercise price of $1.50 per share. The Consent Warrants include a “full ratchet” anti-dilution adjustment in the event that the Company issues any common stock or common stock equivalent at a per share price lower than the applicable exercise price then in effect. The issuance of the Consent Warrants to the Series D Holders was in reliance on the exemption from registration under the Securities Act provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act. Common Stock Issuance On January 5, 2018, the Company entered into a unit purchase agreements with certain accredited investors pursuant to which the Company issued 200,000 shares of our common stock and 100,000 warrants to purchase one share of our common stock, exercisable at a price of $1.50 per share and expiring January 5, 2021, in exchange for aggregate consideration of $299,985, net of expenses of $15 (of which $29,985 were received as common stock subscriptions as of December 31, 2017). In January and February 2018, the Company issued an aggregate of 367,343 shares of common stock in exchange for 280 shares of our Series D 9% Convertible Preferred Stock and accrued dividends. On February 14, 2018, the Company issued an aggregate of 9,919 shares of common stock in exchange for 10 shares of our Series C 9% Convertible Preferred Stock and accrued dividends. On February 1, 2018, the Company granted 200,000 restricted stock units to consultants for services rendered, of which 100,000 vest upon date of grant and 100,000 shares vest at the one-year anniversary of the date of grant provided the consultants are providing services through the vesting date. Options On February 15, 2018, the Company granted our board member, Andrew L. Filler 50,000 options to purchase common stock in connection with his appointment as chairman of our Nominating and Corporate Governance Committee at the exercise price of $1.42 per share for a term of ten years, vesting immediately.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Business and organization BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At December 31, 2017 and 2016, deposits in excess of FDIC limits were $1,297,579 and $805,895, respectively.
Prepaid Expenses Policy [Policy Text Block]	Prepaid Expenses Prepaid expenses are comprised of vendor deposits of $100,000, prepaid insurance and operating expense prepayments.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2017 and 2016, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions (See Note 6 and Note 7).
Research and Development Expense, Policy [Policy Text Block]	Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $4,756,468 and $2,654,501 for the year ended December 31, 2017 and 2016, respectively.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as non-current.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of December 31, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: 2017 2016 Series C convertible preferred stock 656,667 713,333 Series D convertible preferred stock 1,334,000 - Options to purchase common stock 8,510,319 8,245,190 Warrants to purchase common stock 12,789,086 9,128,189 Totals 23,290,072 18,086,712
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2017, there were outstanding stock options to purchase 8,510,319 shares of common stock, 7,347,486 shares of which were vested. As of December 31, 2016, the Company had 8,245,190 options outstanding to purchase shares of common stock, of which 7,028,639 were vested.
Registration Rights Policy [Policy Text Block]	Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. Beginning on October 28, 2016, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement On November 3, 2017, in connection with the Company’s private placement of Series D Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series D Preferred Stock and exercise of the warrants issued to holders of Series D Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series D Preferred Stock and exercise of the warrants on or before December 18, 2017 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by March 18, 2018 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. On December 18, 2017, the Company filed the required registration statement. The Company has estimated the liability under the registration rights agreement at $-0- as of December 31, 2017. Beginning on April 6, 2017, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 1 - SUMMARY OF SIGNIFICA22

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: 2017 2016 Series C convertible preferred stock 656,667 713,333 Series D convertible preferred stock 1,334,000 - Options to purchase common stock 8,510,319 8,245,190 Warrants to purchase common stock 12,789,086 9,128,189 Totals 23,290,072 18,086,712

NOTE 4 - PROPERTY AND EQUIPME23

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of December 31, 2017 and 2016 is summarized as follows: 2017 2016 Computer equipment $ 87,059 $ 84,704 Furniture and fixtures 12,975 10,117 Subtotal 100,034 94,821 Less accumulated depreciation (81,318 ) (70,633 ) Property and equipment, net $ 18,716 $ 24,188

NOTE 5 - ACCOUNTS PAYABLE AND24

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at December 31, 2017 and 2016 consist of the following: 2017 2016 Accrued accounting and legal $ 93,595 $ 120,464 Accrued reimbursements 2,600 43,116 Accrued consulting 109,059 1,192 Accrued research and development expenses 246,030 181,884 Accrued office and other 7,912 10,202 Deferred rent 569 2,912 Accrued settlement related to arbitration 13,333 13,333 $ 473,098 $ 373,103

NOTE 9 - OPTIONS, RESTRICTED 25

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at December 31, 2017: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 3,825,540 6.8 $ 2,662,707 2.01-3.00 4,384,779 3.7 4,384,779 3.01-4.00 300,000 7.3 300,000 8,510,319 5.2 7,347,486
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the 2012 Plan for the years ended December 31, 2017 and 2016 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2016 7,780,190 $ 2.30 6.4 $ - Grants 905,000 1.71 10.0 $ - Exercised - - - Canceled (440,000 ) 2.24 - Outstanding at December 31, 2016 8,245,190 $ 2.24 5.7 $ - Grants 1,680,898 1.50 10.0 $ - Exercised - Canceled (1,415,769 ) $ 2.17 Outstanding at December 31, 2017 8,510,319 $ 2.11 5.2 $ 27,045 Exercisable at December 31, 2017 7,347,486 $ 2.19 4.8 $ 25,394
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following assumptions were used in determining the fair value of employee and vesting non-employee options during the year ended December 31, 2016: Risk-free interest rate 1.08% - 2.04 % Dividend yield 0 % Stock price volatility 109.3% to 122.82 % Expected life 5 – 10 years Weighted average grant date fair value $ 1.47 Risk-free interest rate 2.01% - 2.34 % Dividend yield 0 % Stock price volatility 95.72% to 107.17 % Expected life 5 – 10 years Weighted average grant date fair value $ 1.17
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the two years ended December 31, 2017: Restricted shares issued as of January 1, 2016 175,000 Granted 180,000 Vested (220,000 ) Total restricted shares issued as of December 31, 2016 135,000 Granted - Vested (135,000 ) Vested restricted shares as of December 31, 2017 - Unvested restricted shares as of December 31, 2017 -
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2017: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 8,667,440 February 2018 to May 2021 $ 1.84 35,076 January 2020 $ 1.95 1,689,026 October 2018 to September 2019 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 12,789,086
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the years ended December 31, 2017 and 2016 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2016 7,078,685 $ 2.02 3.0 497,933 Grants 2,049,504 $ 1.74 2.5 - Exercised - $ - - Canceled - $ - - Outstanding at December 31, 2016 9,128,189 $ 1.96 2.1 $ 494,099 Grants 4,479,974 1.50 3.0 - Exercised - Canceled (819,077 ) $ 1.50 Outstanding at December 31, 2017 12,789,086 $ 1.82 1.7 $ 551,636 Vested and expected to vest at December 31, 2017 12,789,086 $ 1.82 1.7 $ 551,636 Exercisable at December 31, 2017 12,789,086 $ 1.82 1.7 $ 551,636

NOTE 10 - FAIR VALUE MEASUREM26

NOTE 10 - FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of December 31, 2017: Warrant Liability Derivative Balance, December 31, 2015 $ 1,621,199 $ 285,157 Total (gains) losses Transfers out due to conversion of Series C Preferred Stock - (103,096 ) Mark to market to December 31, 2016 316,035 106,873 Balance, December 31, 2016 1,937,234 288,934 Initial fair value of derivative at date of issuance of Series D Preferred Stock - 397,162 Initial fair value of warrant liability at date of issuance 652,054 - Transfers out due to conversion of Series C Preferred Stock - (20,757 ) Mark to market to December 31, 2017 (231,048 ) 20,583 Balance, December 31, 2017 2,358,240 685,922 Gain (loss) on change in warrant and derivative liabilities for the year ended December 31, 2016 $ 231,048 $ (20,583 )

NOTE 11 - COMMITMENTS AND CON27

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments under these three agreements are as follows: Year Ending December 31, 2018 $ 112,994 2019 76,995 $ 189,989

NOTE 12 - INCOME TAXES (Tables)

NOTE 12 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The effective rate differs from the statutory rate of 34% for due to the following: 2017 2016 Statutory rate on pre-tax book loss (34.00 )% (34.00 )% (Gain) loss on change in fair value of derivatives (0.56 )% 1.24 % Stock based compensation 12.72 % 17.6 % Fair value of warrant to acquire research and development 1.46 % 0.00 % Other 0.09 % 0.09 % Valuation allowance 20.29 % 15.07 % 0.00 % 0.00 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s deferred taxes as of December 31, 2017 and 2016 consist of the following: 2017 2016 Non-Current deferred tax asset: Net operating loss carry-forwards $ 8,200,000 $ 5,500,000 Valuation allowance (8,200,000 ) (5,500,000 ) Net non-current deferred tax asset $ - $ -

NOTE 1 - SUMMARY OF SIGNIFICA29

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, Uninsured Amount	$ 1,297,579	$ 805,895
Retainage Deposit	100,000
Research and Development Expense	$ 4,756,468	$ 2,654,501
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	8,510,319	8,245,190	7,780,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)	7,347,486	7,028,639
Registration Payment Arrangement, Accrual Carrying Value	$ 0	$ 0
Minimum [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

NOTE 1 - SUMMARY OF SIGNIFICA30

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	23,290,072	18,086,712
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	656,667	713,333
Series D Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,334,000	0
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	8,510,319	8,245,190
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	12,789,086	9,128,189

NOTE 2 - GOING CONCERN AND MA31

NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) - USD ($)	Nov. 03, 2017	Feb. 27, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) [Line Items]
Cash and Cash Equivalents, at Carrying Value			$ 1,547,579	$ 1,055,895	$ 953,234
Working Capital (Deficit)			(2,300,644)
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants			6,041,214
Proceeds from Issuance or Sale of Equity			6,011,229	5,226,368
Net Cash Provided by (Used in) Operating Activities			(7,470,054)	$ (5,107,452)
Series D Preferred Stock [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants	$ 1,929,960
Proceeds from Issuance or Sale of Equity			1,929,960
Working Capital, Excluding Derivative and Warrant Liabilities [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) [Line Items]
Working Capital (Deficit)			$ (743,518)
Subsequent Event [Member]
NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants		$ 1,500,000
Proceeds from Issuance or Sale of Equity		$ 270,000

NOTE 3 - RELATED PARTY TRANSA32

NOTE 3 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Dec. 22, 2017	Nov. 24, 2017	Nov. 09, 2017	Nov. 08, 2017	Nov. 01, 2017	Jun. 16, 2017	Apr. 01, 2017	Feb. 08, 2017	Dec. 29, 2016	Dec. 22, 2016	Dec. 08, 2016	May 04, 2016	Apr. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current (in Dollars)														$ 27,375	$ 15,755
Stock Issued During Period, Shares, Share-based Compensation, Gross											20,875			124,750
Shares Issued, Price Per Share (in Dollars per share)			$ 1.49	$ 1.52		$ 1.37					$ 1.36			$ 1.53
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	105,898	300,000		475,000				130,000	5,000	150,000				1,680,898	905,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)									$ 1.35	$ 1.36				$ 1.50	$ 1.71
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years	10 years		10 years				10 years	10 years	10 years
Stock Repurchased and Retired During Period, Shares							10,744						10,744
Stock Issued During Period, Shares, New Issues						100,000								4,131,536	3,798,417
Chief Executive Officer [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross			50,000	450,000							41,500	250,000
Shares Issued, Price Per Share (in Dollars per share)											$ 1.36	$ 1.93
Chief Financial Officer [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				250,000								200,000
Shares Issued, Price Per Share (in Dollars per share)												$ 1.93
Director [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross			50,000	200,000							41,500
Shares Issued, Price Per Share (in Dollars per share)											$ 1.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	39,926									50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 1.37									$ 1.36
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Director #2 [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross			50,000								20,875
Shares Issued, Price Per Share (in Dollars per share)											$ 1.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	65,972									25,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 1.37									$ 1.36
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Former Director [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										50,000
Director #3 [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross			30,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										25,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)										$ 1.36
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Affiliated Entity [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Description of Transaction					Company will pay Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 300,000 of the Company’s common stock at an exercise of $1.50 per share of common stock, of which 150,000 options vest immediately and 150,000 options are performance conditioned.
Director #4 [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross			30,000
Director #5 [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross			30,000

NOTE 4 - PROPERTY AND EQUIPME33

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Book Value of Distributed Equipment in Connection with Settlement Agreement	$ 3,210
Depreciation	$ 11,698	$ 10,475
Minimum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

NOTE 4 - PROPERTY AND EQUIPME34

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 100,034	$ 94,821
Less accumulated depreciation	(81,318)	(70,633)
Property and equipment, net	18,716	24,188
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	87,059	84,704
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 12,975	$ 10,117

NOTE 5 - ACCOUNTS PAYABLE AND35

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 93,595	$ 120,464
Accrued reimbursements	2,600	43,116
Accrued consulting	109,059	1,192
Accrued research and development expenses	246,030	181,884
Accrued office and other	7,912	10,202
Deferred rent	569	2,912
Accrued settlement related to arbitration	13,333	13,333
	$ 473,098	$ 373,103

NOTE 6 - SERIES C 9% CONVERTI36

NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)	Nov. 03, 2017	Jun. 16, 2017	Mar. 15, 2017	May 11, 2015	Feb. 06, 2013	Jan. 09, 2013	Jul. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Jul. 30, 2016	Jun. 30, 2016	Jun. 29, 2016	May 31, 2016	Feb. 29, 2016	Feb. 28, 2016	Mar. 31, 2015	Jul. 31, 2013	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2015
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted						1,330,627												4,479,974	2,049,504
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 2.61
Warrants, Term of Warrants						5 years
Warrant, Description of Warrant						after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.
Class of Warrant or Right, Outstanding									9,128,189									12,789,086	9,128,189			7,078,685
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)																		$ 543,927
Temporary Equity, Amortization Period																					1 year
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)	$ 397,162								$ 288,934							$ 1,242,590		$ 685,922	$ 288,934
Stock Issued During Period, Shares, New Issues		100,000																4,131,536	3,798,417
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)																		$ 1,929,960	$ 0
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)																		6,041,214
Conversion of Stock, Shares Issued									18,188	19,844	54,759	60,846	197,713	54,859
Conversion of Stock, Shares Converted										20		65
Fair Value Assumptions, Risk Free Interest Rate			1.599%
Fair Value Assumptions, Expected Dividend Rate			0.00%
Fair Value Assumptions, Expected Volatility Rate			105.22%
Dividends Payable, Current (in Dollars)									$ 359,891									447,901	$ 359,891
Registration Payment Arrangement, Term																			In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014.
Registration Payment Arrangement, Accrual Carrying Value (in Dollars)									0									0	$ 0
Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized						4,200
Preferred Stock, Dividend Rate, Percentage						9.00%
Temporary Equity, Par Value (in Dollars)						$ 1,000
Preferred Stock, Dividend Payment Terms						payable quarterly
Preferred Stock, Voting Rights						The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description						The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including: ●incur additional indebtedness;●permit liens on assets;●repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock;●pay cash dividends to our stockholders; and●engage in transactions with affiliates.
Convertible Preferred Stock, Terms of Conversion						Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:  (i)  we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii)  we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii)  we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv)  we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v)  we are party to a change of control transaction,(vi)  we file for bankruptcy or a similar arrangement or are adjudicated insolvent,(vii)  we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.
Temporary Equity, Redemption Price Per Share (in Dollars per share)						$ 1.50
Temporary Equity, Liquidation Preference (in Dollars)									$ 1,070,000									$ 985,000	$ 1,070,000	$ 2,781,000	$ 2,781,000
Stock Issued During Period, Shares, New Issues				450													2,181
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)																	$ 1,814,910
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)				$ 450,000
Conversion of Stock, Shares Issued							19,844	60,846	18,188				197,713		54,859			80,690
Conversion of Stock, Shares Converted							20	65	20		70		236	75	75			85
Fair Value Assumptions, Expected Term																		2 years
Fair Value Assumptions, Expected Dividend Rate																		0.00%
Temporary Equity, Shares Outstanding									1,070									985	1,070
Temporary Equity, Shares Issued									1,070									985	1,070
Dividends Payable, Current (in Dollars)									$ 359,891									$ 419,283	$ 359,891
Full-Ratchet Anti-Dilution Protection Provision [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 1.50
Class of Warrant or Right, Outstanding						2,315,301
Minimum [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate																		0.74%
Fair Value Assumptions, Expected Volatility Rate																		151.00%
Maximum [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate																		1.06%
Fair Value Assumptions, Expected Volatility Rate																		166.00%
Options Held [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other (in Dollars)																				1,303,671
Temporary Equity, Liquidation Preference (in Dollars)																				1,303,671	1,303,671
Warrant [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)																4,097,444
Warrant [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)																				1,064,739
Temporary Equity, Liquidation Preference (in Dollars)																				1,064,739	1,064,739
Issuance Costs [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Liquidation Preference (in Dollars)																				$ 412,590	$ 412,590
Embedded Derivative Financial Instruments [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)																$ 1,242,590
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)																		$ 20,757	103,096
Fair Value Assumptions, Risk Free Interest Rate	1.74%
Fair Value Assumptions, Expected Dividend Rate	0.00%															0.00%		0.00%
Fair Value Assumptions, Expected Volatility Rate	130.00%															141.00%		131.00%
Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)																		$ 20,757	$ 103,096
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term																		1 year 156 days
Fair Value Assumptions, Risk Free Interest Rate																0.56%		1.39%
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term																		3 years 131 days
Fair Value Assumptions, Risk Free Interest Rate																0.89%		1.89%
Bridge Loan [Member] | Series C Preferred Stock [Member]
NOTE 6 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					600

NOTE 7 - WARRANT AND DERIVATI37

NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) - USD ($)	Nov. 03, 2017	Mar. 15, 2017	Mar. 31, 2015	Dec. 31, 2017	Dec. 31, 2016
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)	$ 397,162		$ 1,242,590	$ 685,922	$ 288,934
Derivative Liability, Current (in Dollars)	$ 652,054		4,097,444	2,358,240	1,937,234
Fair Value Assumptions, Risk Free Interest Rate		1.599%
Fair Value Assumptions, Expected Dividend Rate		0.00%
Fair Value Assumptions, Expected Volatility Rate		105.22%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)				$ 210,465	$ (422,908)
Embedded Derivative Financial Instruments [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)			$ 1,242,590
Fair Value Assumptions, Risk Free Interest Rate	1.74%
Fair Value Assumptions, Expected Dividend Rate	0.00%		0.00%	0.00%
Fair Value Assumptions, Expected Volatility Rate	130.00%		141.00%	131.00%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)				$ (20,583)
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.56%	1.39%
Fair Value Assumptions, Expected Term				1 year 156 days
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
NOTE 7 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.89%	1.89%
Fair Value Assumptions, Expected Term				3 years 131 days

NOTE 8 - STOCKHOLDER EQUITY (De

NOTE 8 - STOCKHOLDER EQUITY (Details)	Nov. 06, 2017$ / sharesshares	Nov. 03, 2017USD ($)$ / sharesshares	Jun. 16, 2017$ / sharesshares	Apr. 01, 2017shares	Mar. 15, 2017USD ($)$ / shares	Dec. 08, 2016$ / sharesshares	May 11, 2015USD ($)shares	Jan. 09, 2013$ / sharesshares	Jul. 31, 2017shares	Jun. 30, 2017shares	Apr. 30, 2017shares	Dec. 31, 2016USD ($)$ / sharesshares	Jul. 30, 2016shares	Jun. 30, 2016shares	Jun. 29, 2016shares	May 31, 2016shares	Feb. 29, 2016shares	Feb. 28, 2016shares	Jul. 31, 2013shares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Nov. 09, 2017$ / shares	Nov. 08, 2017$ / shares	Nov. 18, 2016shares	Nov. 17, 2016shares
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized												1,000,000								1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares												$ 0.001								$ 0.001	$ 0.001
Conversion of Stock, Shares Issued												18,188	19,844	54,759	60,846	197,713	54,859
Conversion of Stock, Shares Converted													20		65
Convertible Preferred Dividends, Net of Tax (in Dollars) | $																				$ 116,868
Stock Issued During Period, Shares, New Issues			100,000																	4,131,536	3,798,417
Class of Warrant or Rights, Granted								1,330,627												4,479,974	2,049,504
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares								$ 2.61
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars) | $																				$ 6,041,214
Payments of Stock Issuance Costs (in Dollars) | $																				$ 186,075	$ 490,543
Warrants, Fair Value of Warrants, Granted (in Dollars) | $					$ 543,927
Common Stock, Shares Authorized												200,000,000								200,000,000	200,000,000			200,000,000	50,000,000
Common Stock, Shares, Outstanding												22,588,184								29,321,204	22,588,184
Common Stock, Shares, Issued												22,588,184								29,321,204	22,588,184
Stock Issued During Period, Shares, Share-based Compensation, Gross						20,875														124,750
Shares Issued, Price Per Share (in Dollars per share) | $ / shares			$ 1.37			$ 1.36														$ 1.53		$ 1.49	$ 1.52
Stock Issued During Period, Value, Issued for Services (in Dollars) | $																				$ 3,386,617	$ 2,471,050
Proceeds from Issuance or Sale of Equity (in Dollars) | $																				$ 6,011,229	$ 5,226,368
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																				0.00%	0.00%
Share Price (in Dollars per share) | $ / shares					$ 1.37															$ 1.44
Stock Issued During Period, Shares, Restricted Stock Award, Gross																				135,000
Stock Repurchased and Retired During Period, Shares				10,744							10,744
Registration Payment Arrangement, Accrual Carrying Value (in Dollars) | $												$ 0								$ 0	$ 0
Series A Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized												200								200	200
Series B Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized												600								600	600
Series C Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized												4,200								4,200	4,200
Conversion of Stock, Shares Issued									19,844	60,846		18,188				197,713		54,859		80,690
Conversion of Stock, Shares Converted									20	65		20		70		236	75	75		85
Temporary Equity, Shares Issued												1,070								985	1,070
Temporary Equity, Shares Outstanding												1,070								985	1,070
Preferred Stock, Dividend Rate, Percentage								9.00%
Convertible Preferred Stock, Terms of Conversion								Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that:  (i)  we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered,(ii)  we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered,(iii)  we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv)  we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered,(v)  we are party to a change of control transaction,(vi)  we file for bankruptcy or a similar arrangement or are adjudicated insolvent,(vii)  we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.
Stock Issued During Period, Shares, New Issues							450												2,181
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars) | $							$ 450,000
Series D Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized																				1,400
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares		$ 0.001										$ 0.001								$ 0.001	$ 0.001
Conversion of Stock, Shares Converted																				1,334
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $ / shares		$ 1,500
Preferred Stock, Conversion Price (in Dollars per share)		1.50
Preferred Stock, Dividend Rate, Percentage		9.00%
Convertible Preferred Stock, Terms of Conversion		Upon the conversion of Preferred Shares prior to November 3, 2020, the Company shall also pay to the Holders of the Preferred Shares so converted cash, or at the Company’s option, Common Stock or a combination thereof, with respect to the Preferred Shares so converted in an amount equal to $270 per $1,000 of Stated Value of the Preferred Shares being converted, less the amount of all prior dividends paid on such converted Preferred Shares before the relevant date of conversion.
Stock Issued During Period, Shares, New Issues		1,334
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars) | $		$ 1,929,960
Payments of Stock Issuance Costs (in Dollars) | $		$ 70,040
Dividends Payable (in Dollars) | $																				$ 28,618
Proceeds from Issuance or Sale of Equity (in Dollars) | $																				$ 1,929,960
Private Placement [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Rights, Granted																				2,246,300	2,040,504
Exchange of Outstanding Warrants for Class B Warrants [Member] | Series C Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Conversion of Stock, Shares Issued														54,759
Conversion of Stock, Shares Converted														70
Exchange of Outstanding Warrants for Class B Warrants [Member] | Series D Preferred Stock [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 1.50
Warrants, Fair Value of Warrants, Granted (in Dollars) | $		$ 780,506
Sale of Class A Warrants [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Rights, Granted		667,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 1.75
Class A Warrant Adjustment [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares	$ 1.50
Warrant Adjustment, Additional Shares Issued Upon Exercise	111,167
Services Provided [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares												1.93									$ 1.93
Stock Issued During Period, Shares, Issued for Services																					545,000
Stock Issued During Period, Value, Issued for Services (in Dollars) | $																					$ 1,051,850
Exercise of Options [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross																					83,545
Stock Issued During Period, Value, Stock Options Exercised (in Dollars) | $																					$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																					0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																					122.82%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																					1.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																					5 years
Share Price (in Dollars per share) | $ / shares												1.84									$ 1.84
Common Stock Issued for Services [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services																				446,788
Stock Issued During Period, Value, Issued for Services (in Dollars) | $																				$ 681,367
2012 Equity Incentive Plan [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross																					790,000
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars) | $																					$ 1,419,200
Shares Issued, Price Per Share (in Dollars per share) | $ / shares												$ 1.80								$ 1.48	$ 1.80
Stock Issued During Period, Shares, Issued for Services																				1,825,000
Stock Issued During Period, Value, Issued for Services (in Dollars) | $																				$ 2,705,250
Restricted Stock Units (RSUs) [Member]
NOTE 8 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities																					220,000

NOTE 9 - OPTIONS, RESTRICTED 39

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - USD ($)	Dec. 29, 2017	Dec. 22, 2017	Nov. 24, 2017	Nov. 08, 2017	Nov. 06, 2017	Nov. 03, 2017	Oct. 11, 2017	Sep. 18, 2017	Aug. 18, 2017	Jul. 13, 2017	Jun. 30, 2017	Jun. 20, 2017	May 17, 2017	Apr. 29, 2017	Apr. 06, 2017	Mar. 31, 2017	Mar. 15, 2017	Mar. 10, 2017	Feb. 10, 2017	Feb. 09, 2017	Feb. 08, 2017	Dec. 29, 2016	Dec. 22, 2016	Dec. 16, 2016	Nov. 23, 2016	Oct. 28, 2016	Sep. 19, 2016	Sep. 07, 2016	Aug. 30, 2016	Aug. 24, 2016	Jun. 01, 2016	May 18, 2016	Apr. 29, 2016	Apr. 19, 2016	Apr. 01, 2016	Mar. 09, 2016	Feb. 09, 2016	May 05, 2015	Jan. 09, 2013	Oct. 19, 2012	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		105,898	300,000	475,000																	130,000	5,000	150,000																			1,680,898	905,000
Share Price (in Dollars per share)																	$ 1.37																									$ 1.44
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years	10 years	10 years																	10 years	10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																																										0	0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																																										0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)																																										$ 1.17	$ 1.47
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)		$ 1.37	$ 1.50	$ 1.57																	$ 1.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			150,000	237,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)																						$ 1.35	$ 1.36																			$ 1.50	$ 1.71
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			150,000 vesting immediately and 150,000 performance contingent	237,500 vesting immediately and 237,500 at one year anniversary
Share-based Compensation (in Dollars)																																										$ 4,749,470	$ 5,999,750
Class of Warrant or Rights, Granted																																							1,330,627			4,479,974	2,049,504
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																																							$ 2.61
Warrants, Fair Value of Warrants, Granted (in Dollars)																	$ 543,927
Fair Value Assumptions, Expected Volatility Rate																	105.22%
Fair Value Assumptions, Risk Free Interest Rate																	1.599%
Fair Value Assumptions, Expected Dividend Rate																	0.00%
Class of Warrant or Rights, Cancelled																																										819,077	0
Warrants at $1.95 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted														567,866													35,000		152,513					84,980	100,327	100,000	25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)														$ 1.95													$ 1.95		$ 1.95					$ 1.95	$ 1.95	$ 1.95	$ 1.95					$ 1.95
Warrant, Expriation Date																											Sep. 19, 2019		Aug. 30, 2019				Apr. 29, 2019	Apr. 19, 2019	Apr. 1, 2019	Mar. 9, 2019	Feb. 9, 2019
Warrants at $1.50 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted	230,334				206,668	780,506	193,334	51,668	175,500	133,501	108,334	10,000	186,957		288,300	157,250	630,000	197,159	300,628	45,001			115,000	456,668	50,002	173,284												6,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50				$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50		$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50			$ 1.50	$ 1.50	$ 1.50	$ 1.50												$ 1.50				$ 1.50
Warrant, Expriation Date	Dec. 29, 2020				Nov. 6, 2020	Nov. 3, 2020	Oct. 11, 2020	Sep. 18, 2020	Aug. 18, 2020	Jul. 13, 2020	Jun. 30, 2020	Jun. 20, 2020	May 17, 2020		Apr. 6, 2020	Mar. 31, 2020	Mar. 15, 2020	Mar. 10, 2020	Feb. 10, 2020				Dec. 22, 2019	Dec. 16, 2019	Nov. 23, 2019	Oct. 28, 2019												May 5, 2020
Class of Warrant or Rights, Cancelled						780,505
Warrants at $2.10 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted																				38,572											38,572
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																				$ 2.10											$ 2.10
Warrant, Expriation Date																															Jun. 1, 2019
2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services																																										1,825,000
Maximum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																																										107.17%	122.82%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																																											2.04%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																																										10 years	10 years
Minimum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																																										95.72%	109.30%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																																											1.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																																										5 years	5 years
Series D Preferred Stock [Member] | Warrants at $1.50 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted					111,167	667,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					$ 1.50	$ 1.50
Warrant, Expriation Date					May 3, 2021	May 3, 2021
Warrants Modified					667,000
Services Provided [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			50,000	200,000
Stock Issued During Period, Shares, Issued for Services																																											545,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years	10 years
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)			$ 1.45	$ 1.57
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				50,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				50,000 vesting immediately and 50,000 vesting each anniversary through November 8, 2020
Services Provided #2 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			420,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)			$ 1.45
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			120,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			120,000 vesting immediately; 50,000 vesting on two year anniversary and 250,000 performance contingent
Warrants Issued to Placement Agents [Member] | Warrants at $1.50 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted																																	96,256	17,996	18,040	12,000	6,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																																	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50
Warrant, Expriation Date																																		Apr. 19, 2019	Apr. 1, 2019	Mar. 9, 2019	Feb. 9, 2019
Warrants Issued to Placement Agents [Member] | Maximum [Member] | Warrants at $1.50 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Warrant, Expriation Date																																	Apr. 29, 2019
Warrants Issued to Placement Agents [Member] | Minimum [Member] | Warrants at $1.50 [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Warrant, Expriation Date																																	Oct. 23, 2018
Warrant [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation (in Dollars)																																										$ 0	$ 56,931
Officers, Directors and Key Consultants [Member] | 2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																																										1,680,898	750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period																																											100,000
Stock Issued During Period, Shares, Issued for Services																																										2,009,750	723,545
Employee Stock Option [Member] | 2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																																								15,186,123
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award																																								the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
Common Stock, Capital Shares Reserved for Future Issuance																																								227,388
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																														65,000		685,000
Share Price (in Dollars per share)																																										$ 1.44
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)																																$ 1.84
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																														10 years		10 years
Stock Issued During Period, Shares, Conversion of Convertible Securities																																									83,545
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																																									100,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																																									0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																																									122.82%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																																									1.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																																									5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)																																									$ 1.84
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)																														$ 1.33
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)																																										$ 1,269,591	$ 2,801,948
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)																																										979,812	$ 310,817
Employee Stock Option [Member] | Maximum [Member] | 2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																																								10 years
Employee Stock Option [Member] | Share-based Compensation Award, Tranche One [Member] | 2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares																														12,500
Employee Stock Option [Member] | Share-based Compensation Award, Tranche Two [Member] | 2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares																														37,500
Employee Stock Option [Member] | Share-based Compensation Award, Tranche Three [Member] | 2012 Equity Incentive Plan [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares																														15,000
Restricted Stock Units (RSUs) [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																												1 year
Stock Issued During Period, Shares, Conversion of Convertible Securities																																											220,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																												180,000
Share-based Compensation (in Dollars)																																										$ 93,261	$ 213,174

NOTE 9 - OPTIONS, RESTRICTED 40

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	8,510,319	8,245,190	7,780,190
Options Outstanding, Weighted Average Remaining Life	5 years 73 days	5 years 255 days	6 years 146 days
Options Exercisable, Number of Options	7,347,486
Options at $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 1.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 2
Options Outstanding, Number of Options	3,825,540
Options Outstanding, Weighted Average Remaining Life	6 years 292 days
Options Exercisable, Number of Options	2,662,707
Options at $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 2.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 3
Options Outstanding, Number of Options	4,384,779
Options Outstanding, Weighted Average Remaining Life	3 years 255 days
Options Exercisable, Number of Options	4,384,779
Options at $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 3.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 4
Options Outstanding, Number of Options	300,000
Options Outstanding, Weighted Average Remaining Life	7 years 109 days
Options Exercisable, Number of Options	300,000

NOTE 9 - OPTIONS, RESTRICTED 41

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	Dec. 22, 2017	Nov. 24, 2017	Nov. 08, 2017	Feb. 08, 2017	Dec. 29, 2016	Dec. 22, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares							8,510,319	8,245,190	7,780,190
Options Outstanding, Weighted-Average Exercise Price							$ 2.11	$ 2.24	$ 2.30
Options Outstanding, Weighted-Average Remaining Contractual Term							5 years 73 days	5 years 255 days	6 years 146 days
Options Outstanding, Aggregate Intrinsic Value							$ 27,045	$ 0	$ 0
Options Exercisable, Shares							7,347,486	7,028,639
Options Exercisable, Weighted-Average Exercise Price							$ 2.19
Options Exercisable, Weighted-Average Remaining Contractual Term							4 years 292 days
Options Exercisable, Aggregate Intrinsic Value							$ 25,394
Options Granted, Shares	105,898	300,000	475,000	130,000	5,000	150,000	1,680,898	905,000
Options Granted, Weighted-Average Exercise Price					$ 1.35	$ 1.36	$ 1.50	$ 1.71
Options Granted, Weighted-Average Remaining Contractual Term							10 years	10 years
Options Exercised, Shares							0	0
Options Exercised, Weighted-Average Exercise Price							$ 0	$ 0
Options Canceled, Shares							(1,415,769)	(440,000)
Options Canceled, Weighted-Average Exercise Price							$ 2.17	$ 2.24

NOTE 9 - OPTIONS, RESTRICTED 42

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield	0.00%	0.00%
Weighted average grant date fair value (in Dollars per share)	$ 1.17	$ 1.47
Minimum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate		1.08%
Stock price volatility	95.72%	109.30%
Expected life	5 years	5 years
Maximum [Member]
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate		2.04%
Stock price volatility	107.17%	122.82%
Expected life	10 years	10 years

NOTE 9 - OPTIONS, RESTRICTED 43

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued	135,000	175,000
Restricted shares Granted	0	180,000
Restricted shares Vested	(135,000)	(220,000)
Vested restricted shares	0
Unvested restricted shares	0
Restricted shares issued		135,000

NOTE 9 - OPTIONS, RESTRICTED 44

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares

12 Months Ended

Dec. 31, 2017

Dec. 29, 2017

Nov. 06, 2017

Nov. 03, 2017

Oct. 11, 2017

Sep. 18, 2017

Aug. 18, 2017

Jul. 13, 2017

Jun. 30, 2017

Jun. 20, 2017

May 17, 2017

Apr. 29, 2017

Apr. 06, 2017

Mar. 31, 2017

Mar. 15, 2017

Mar. 10, 2017

Feb. 10, 2017

Feb. 09, 2017

Dec. 31, 2016

Dec. 22, 2016

Dec. 16, 2016

Nov. 23, 2016

Oct. 28, 2016

Sep. 19, 2016

Aug. 30, 2016

Apr. 19, 2016

Apr. 01, 2016

Mar. 09, 2016

Feb. 09, 2016

Dec. 31, 2015

May 05, 2015

Jan. 09, 2013

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2.61

Number of Warrants Outstanding

12,789,086

9,128,189

7,078,685

Warrants at $0.001 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 0.001

Number of Warrants Outstanding

383,320

Expiration Date, Warrants

January 2,020

Warrants at $1.50 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

$ 1.50

Number of Warrants Outstanding

8,667,440

Expiration Date, Warrants

February 2018 to May 2021

Warrants at $1.84 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 1.84

Number of Warrants Outstanding

35,076

Expiration Date, Warrants

January 2,020

Warrants at $1.95 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 1.95

$ 1.95

$ 1.95

$ 1.95

$ 1.95

$ 1.95

$ 1.95

$ 1.95

Number of Warrants Outstanding

1,689,026

Expiration Date, Warrants

October 2018 to September 2019

Warrants at $2.00 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2

Number of Warrants Outstanding

100,000

Expiration Date, Warrants

August 2,018

Warrants at $2.02 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2.02

Number of Warrants Outstanding

30,755

Expiration Date, Warrants

January 2,020

Warrants at $2.50 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2.50

Number of Warrants Outstanding

100,000

Expiration Date, Warrants

August 2,018

Warrants at $2.75 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 2.75

Number of Warrants Outstanding

228,720

Expiration Date, Warrants

August 2019 to September 2019

Warrants at $3.67 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 3.67

Number of Warrants Outstanding

214,193

Expiration Date, Warrants

December 2018 to January 2019

Warrants at $3.75 [Member]

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

Exercise Price, Warrants (in Dollars per share)

$ 3.75

Number of Warrants Outstanding

1,340,556

Expiration Date, Warrants

April 2019 to March 2020

NOTE 9 - OPTIONS, RESTRICTED 45

NOTE 9 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	Dec. 31, 2015	Jan. 09, 2013	Dec. 31, 2017	Dec. 31, 2016
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares	7,078,685		12,789,086	9,128,189
Warrants Outstanding, Weighted-Average Exercise Price	$ 2.02		$ 1.82	$ 1.96
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years		1 year 255 days	2 years 36 days
Warrants Outstanding, Aggregate Intrinsic Value	$ 497,933		$ 551,636	$ 494,099
Warrants Vested and expected to vest, Shares			12,789,086
Warrants Vested and expected to vest, Weighted-Average Exercise Price			$ 1.82
Warrants Vested and expected to vest, Weighted-Average Remaining Contractual Term			1 year 255 days
Warrants Vested and expected to vest, Aggregate Intrinsic Value			$ 551,636
Warrants Exercisable, Shares			12,789,086
Warrants Exercisable, Weighted-Average Exercise Price			$ 1.82
Warrants Exercisable, Weighted-Average Remaining Contractual Term			1 year 255 days
Warrants Exercisable, Aggregate Intrinsic Value			$ 551,636
Warrants Granted, Shares		1,330,627	4,479,974	2,049,504
Warrants Granted, Weighted-Average Exercise Price			$ 1.50	$ 1.74
Warrants Granted, Weighted-Average Remaining Contractual Term			3 years	2 years 6 months
Warrants Exercised, Shares			0	0
Warrants Exercised, Weighted-Average Exercise Price			$ 0	$ 0
Warrants Canceled, Shares			(819,077)	0
Warrants Canceled, Weighted-Average Exercise Price			$ 1.50	$ 0

NOTE 10 - FAIR VALUE MEASUREM46

NOTE 10 - FAIR VALUE MEASUREMENT (Details) - USD ($)	Dec. 31, 2017	Nov. 03, 2017	Dec. 31, 2016	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 685,922	$ 397,162	$ 288,934	$ 1,242,590
Derivative Liability, Current	$ 2,358,240	$ 652,054	$ 1,937,234	$ 4,097,444

NOTE 10 - FAIR VALUE MEASUREM47

NOTE 10 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Loss on change in warrant and derivative liabilities for the year ended December 31, 2016	$ 210,465	$ (422,908)
Initial fair value	1,049,216	0
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	2,358,240	1,937,234	$ 1,621,199
Loss on change in warrant and derivative liabilities for the year ended December 31, 2016	231,048
Initial fair value	652,054
Transfers out	0	0
Mark to market	(231,048)	316,035
Warrant [Member] | Series D Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Initial fair value	0
Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	685,922	288,934	$ 285,157
Loss on change in warrant and derivative liabilities for the year ended December 31, 2016	(20,583)
Initial fair value	0
Transfers out	(20,757)	(103,096)
Mark to market	20,583	$ 106,873
Embedded Derivative Financial Instruments [Member] | Series D Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Initial fair value	$ 397,162

NOTE 11 - COMMITMENTS AND CON48

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details)	Dec. 29, 2017$ / sharesshares	Dec. 22, 2017$ / sharesshares	Nov. 24, 2017$ / sharesshares	Nov. 08, 2017$ / sharesshares	Nov. 06, 2017$ / sharesshares	Nov. 03, 2017$ / sharesshares	Oct. 11, 2017$ / sharesshares	Sep. 18, 2017$ / sharesshares	Aug. 18, 2017$ / sharesshares	Jul. 13, 2017$ / sharesshares	Jun. 30, 2017$ / sharesshares	Jun. 20, 2017$ / sharesshares	May 17, 2017$ / sharesshares	Apr. 06, 2017$ / sharesshares	Mar. 31, 2017$ / sharesshares	Mar. 15, 2017$ / sharesshares	Mar. 10, 2017$ / sharesshares	Feb. 10, 2017$ / sharesshares	Feb. 09, 2017$ / sharesshares	Feb. 08, 2017$ / sharesshares	Dec. 29, 2016shares	Dec. 22, 2016$ / sharesshares	Dec. 16, 2016$ / sharesshares	Nov. 23, 2016$ / sharesshares	Oct. 28, 2016$ / sharesshares	May 05, 2015$ / sharesshares	Jul. 15, 2014USD ($)$ / sharesshares	Jan. 09, 2013$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016shares
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Agreement Term																10 years
Class of Warrant or Rights, Granted																												1,330,627	4,479,974	2,049,504
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares																												$ 2.61
Number of Directors																											8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		105,898	300,000	475,000																130,000	5,000	150,000							1,680,898	905,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares		$ 1.37	$ 1.50	$ 1.57																$ 1.55
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years	10 years	10 years																10 years	10 years	10 years
Parking Space Leases [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals (in Dollars) | $																													$ 978
Warrants at $1.50 [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Class of Warrant or Rights, Granted	230,334				206,668	780,506	193,334	51,668	175,500	133,501	108,334	10,000	186,957	288,300	157,250	630,000	197,159	300,628	45,001			115,000	456,668	50,002	173,284	6,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares	$ 1.50				$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50			$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50			$ 1.50
Minimum [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Percentage of Net Sales																1.00%
Maximum [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Percentage of Net Sales																2.00%
Chief Executive Officer [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Deferred Compensation Arrangement with Individual, Requisite Service Period																											3 years
Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																											1,265,769
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares																											$ 2.21
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																											10 years
Chief Executive Officer [Member] | Employee Agreement [Member] | Minimum [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Qualified Financing Amount (in Dollars) | $																											$ 3,500,000
Chief Executive Officer [Member] | Employee Agreement [Member] | Maximum [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment (in Dollars) | $																											$ 325,000
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche One [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																											542,473
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche Two [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares																											180,824
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche Three [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares																											180,824
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche Four [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares																											180,824
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche Five [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares																											180,824
Chief Executive Officer [Member] | Employee Agreement [Member] | Options Vesting in Eleven Equal Installments [Member] | Share-based Compensation Award, Tranche One [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares																											45,206
Chief Executive Officer [Member] | Employee Agreement [Member] | Final Installment of Vested Options [Member] | Share-based Compensation Award, Tranche One [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares																											45,207
Annual Salary [Member] | Chief Executive Officer [Member] | Employee Agreement [Member] | Minimum [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment (in Dollars) | $																											$ 275,000
Signing Bonus [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment (in Dollars) | $																											$ 30,000

NOTE 11 - COMMITMENTS AND CON49

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases	Dec. 31, 2017USD ($)
Schedule of Future Minimum Rental Payments for Operating Leases [Abstract]
2,018	$ 112,994
2,019	76,995
	$ 189,989

NOTE 12 - INCOME TAXES (Details

NOTE 12 - INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 24,000,000
Operating Loss Carryforwards, Expiration Date 1	2,036
Deferred Tax Assets, Valuation Allowance	$ 8,200,000	$ 5,500,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%

NOTE 12 - INCOME TAXES (Detai51

NOTE 12 - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Statutory rate on pre-tax book loss	(34.00%)	(34.00%)
(Gain) loss on change in fair value of derivatives	(0.56%)	1.24%
Stock based compensation	12.72%	17.60%
Fair value of warrant to acquire research and development	1.46%	0.00%
Other	0.09%	0.09%
Valuation allowance	20.29%	15.07%
	0.00%	0.00%

NOTE 12 - INCOME TAXES (Detai52

NOTE 12 - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Non-Current deferred tax asset:
Net operating loss carry-forwards	$ 8,200,000	$ 5,500,000
Valuation allowance	(8,200,000)	(5,500,000)
Net non-current deferred tax asset	$ 0	$ 0

NOTE 13 - SUBSEQUENT EVENTS (De

NOTE 13 - SUBSEQUENT EVENTS (Details) - USD ($)	Feb. 16, 2018	Feb. 15, 2018	Feb. 14, 2018	Feb. 01, 2018	Jan. 05, 2018	Dec. 22, 2017	Nov. 24, 2017	Nov. 08, 2017	Nov. 03, 2017	Jun. 16, 2017	Feb. 08, 2017	Dec. 29, 2016	Dec. 22, 2016	May 11, 2015	Jan. 09, 2013	Jan. 31, 2018	Jul. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Jul. 30, 2016	Jun. 30, 2016	Jun. 29, 2016	May 31, 2016	Feb. 29, 2016	Feb. 28, 2016	Feb. 27, 2018	Jul. 31, 2013	Dec. 31, 2017	Dec. 31, 2016
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues										100,000																		4,131,536	3,798,417
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)																			$ 0.001									$ 0.001	$ 0.001
Class of Warrant or Rights, Granted															1,330,627													4,479,974	2,049,504
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)															$ 2.61
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)																												$ 6,041,214
Proceeds from Issuance or Sale of Equity (in Dollars)																												6,011,229	$ 5,226,368
Payments of Stock Issuance Costs (in Dollars)																												$ 186,075	$ 490,543
Conversion of Stock, Shares Issued																			18,188	19,844	54,759	60,846	197,713	54,859
Conversion of Stock, Shares Converted																				20		65
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						105,898	300,000	475,000			130,000	5,000	150,000															1,680,898	905,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)												$ 1.35	$ 1.36															$ 1.50	$ 1.71
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years	10 years	10 years			10 years	10 years	10 years
Series D Preferred Stock [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues									1,334
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)									$ 0.001										$ 0.001									$ 0.001	$ 0.001
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)									$ 1,929,960
Proceeds from Issuance or Sale of Equity (in Dollars)																												$ 1,929,960
Payments of Stock Issuance Costs (in Dollars)									$ 70,040
Conversion of Stock, Shares Converted																												1,334
Series C Preferred Stock [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues														450													2,181
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)														$ 450,000
Conversion of Stock, Shares Issued																	19,844	60,846	18,188				197,713		54,859			80,690
Conversion of Stock, Shares Converted																	20	65	20		70		236	75	75			85
Unit Purchase Agreements [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable (in Dollars)																												$ 29,985
Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)																$ 3,044,162
Stock Issued During Period, Shares, New Issues			9,919
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)																										$ 1,500,000
Proceeds from Issuance or Sale of Equity (in Dollars)																										$ 270,000
Conversion of Stock, Shares Issued																										367,343
Stock Issued During Period, Shares, Issued for Services				200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)		$ 1.42
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Subsequent Event [Member] | Series E Preferred Stock [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.001
Class of Warrant or Rights, Granted	500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.75
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)	$ 1,500,000
Subsequent Event [Member] | Series D Preferred Stock [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Converted																										280
Subsequent Event [Member] | Series C Preferred Stock [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Class of Warrant or Rights, Granted			10
Subsequent Event [Member] | Consent Agreement, Series D Holders [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Class of Warrant or Rights, Granted	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50
Subsequent Event [Member] | Unit Purchase Agreements [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					200,000
Class of Warrant or Rights, Granted					100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					$ 1.50
Proceeds from Issuance or Sale of Equity (in Dollars)					$ 299,985
Payments of Stock Issuance Costs (in Dollars)					$ 15
Subsequent Event [Member] | Share-based Compensation Award, Tranche One [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services				100,000
Subsequent Event [Member] | Share-based Compensation Award, Tranche Two [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services				100,000